Cytokine profile determined by data-mining analysis set into clusters of non-small-cell lung cancer patients according to prognosis.

BACKGROUND Immunoregulatory cytokines may play a fundamental role in tumor growth and metastases. Their effects are mediated through complex regulatory networks. Human cytokine profiles could define patient subgroups and represent new potential biomarkers. The aim of this study was to associate a cytokine profile obtained through data mining with the clinical characteristics of patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS We conducted a prospective study of the plasma levels of 14 immunoregulatory cytokines by ELISA and a cytometric bead array assay in 110 NSCLC patients before chemotherapy and 25 control subjects. Cytokine levels and data-mining profiles were associated with clinical, quality of life and pathological outcomes. RESULTS NSCLC patients had higher levels of interleukin (IL)-6, IL-8, IL-12p70, IL-17a and interferon (IFN)-γ, and lower levels of IL-33 and IL-29 compared with controls. The pro-inflammatory cytokines IL-1b, IL-6 and IL-8 were associated with lower hemoglobin levels, worse functional performance status (Eastern Cooperative Oncology Group, ECOG), fatigue and hyporexia. The anti-inflammatory cytokines IL-4, IL-10 and IL-33 were associated with anorexia and lower body mass index. We identified three clusters of patients according to data-mining analysis with different overall survival (OS; 25.4, 16.8 and 5.09 months, respectively, P = 0.0012). Multivariate analysis showed that ECOG performance status and data-mining clusters were significantly associated with OS (RR 3.59, [95% CI 1.9-6.7], P < 0.001 and 2.2, [1.2-3.8], P = 0.005). CONCLUSION Our results provide evidence that complex cytokine networks may be used to identify patient subgroups with different prognoses in advanced NSCLC. These cytokines may represent potential biomarkers, particularly in the immunotherapy era in cancer research.

[1]  A. Mohar,et al.  Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non-small cell lung cancer: randomised trial. , 2014, Clinical nutrition.

[2]  L. Collette,et al.  Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation fo , 2014, European journal of cancer.

[3]  X. Paoletti,et al.  Dose‐finding design using mixed‐effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials , 2013, Statistics in medicine.

[4]  R. Pfeiffer,et al.  Circulating inflammation markers and prospective risk for lung cancer. , 2013, Journal of the National Cancer Institute.

[5]  L. McShane,et al.  Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  J. Bower,et al.  Inflammation and cancer-related fatigue: Mechanisms, contributing factors, and treatment implications , 2013, Brain, Behavior, and Immunity.

[7]  L. Oñate-Ocaña,et al.  Health-related quality of life in patients with lung cancer: validation of the Mexican-Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. , 2012, Lung cancer.

[8]  L. Oñate-Ocaña,et al.  Association of Nutrition Parameters Including Bioelectrical Impedance and Systemic Inflammatory Response With Quality of Life and Prognosis in Patients With Advanced Non-Small-Cell Lung Cancer: A Prospective Study , 2012, Nutrition and cancer.

[9]  Takashi Suzuki,et al.  Antitumor activity of type III interferon alone or in combination with type I interferon against human non‐small cell lung cancer , 2011, Cancer science.

[10]  D. Bandyopadhyay,et al.  Proportional odds model for dose‐finding clinical trial designs with ordinal toxicity grading , 2011, Statistics in medicine.

[11]  J. Scheller,et al.  The pro- and anti-inflammatory properties of the cytokine interleukin-6. , 2011, Biochimica et biophysica acta.

[12]  M. Neurath,et al.  IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. , 2011, Cytokine & growth factor reviews.

[13]  R. Sabat,et al.  IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties. , 2010, Cytokine & growth factor reviews.

[14]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[15]  S. Costantini,et al.  An approach for understanding the inflammation and cancer relationship. , 2009, Immunology letters.

[16]  Alberto Mantovani,et al.  Cytokines as a key component of cancer-related inflammation. , 2008, Cytokine.

[17]  A. Mantovani,et al.  Cancer and inflammation: a complex relationship. , 2008, Cancer letters.

[18]  C. Dinarello Historical insights into cytokines , 2007, European journal of immunology.

[19]  S. Brand,et al.  Novel interferon-λs induce antiproliferative effects in neuroendocrine tumor cells , 2006 .

[20]  O. Feron,et al.  Innate immunity and angiogenesis. , 2004, Circulation research.

[21]  D. Lacombe,et al.  Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  N. Songür,et al.  Serum Interleukin-6 Levels Correlate with Malnutrition and Survival in Patients with Advanced Non-Small Cell Lung Cancer , 2004, Tumori.

[23]  J. Steinke,et al.  2. Cytokines and chemokines. , 2003, The Journal of allergy and clinical immunology.

[24]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[25]  Y K Cheung,et al.  Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.

[26]  G. Trinchieri,et al.  Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers , 1991, The Journal of experimental medicine.

[27]  T. Kishimoto,et al.  The biology of interleukin-6. , 1989, Blood.

[28]  A. Jemal,et al.  Cancer statistics, 2014 , 2014, CA: a cancer journal for clinicians.

[29]  อนิรุธ สืบสิงห์ Data Mining Practical Machine Learning Tools and Techniques , 2014 .

[30]  Kawsar Ahmed,et al.  Early detection of lung cancer risk using data mining. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[31]  V. Brouste,et al.  Pegylated liposomal doxorubicin and cyclophosphamide in early recurrent ovarian carcinoma: phase I dose-finding study , 2013, Cancer Chemotherapy and Pharmacology.

[32]  P. Varlet,et al.  Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. , 2011, Neuro-oncology.

[33]  S. Brand,et al.  Novel interferon-lambdas induce antiproliferative effects in neuroendocrine tumor cells. , 2006, Biochemical and biophysical research communications.

[34]  J. Pollard Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[35]  Larry Borish,et al.  Cytokines and chemokines , 2003 .

[36]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.